Semaglutide and tirzepatide are two of the most discussed prescription options in modern medical weight management, but they are not interchangeable and neither is automatically the right choice for every patient.
Semaglutide acts through the GLP-1 pathway, while tirzepatide acts through both GIP and GLP-1 pathways. Those pharmacologic differences can influence appetite, glucose regulation, gastrointestinal side effects and treatment response.
Medication selection should consider medical history, BMI, weight-related conditions, diabetes status, prior medication response, gastrointestinal tolerance, concurrent medications, goals and long-term treatment strategy.
Both medications require attention to dose escalation, side effects, hydration, nutrition and changes in other medications. Physician follow-up can help identify problems early and adjust treatment safely.
A medical plan should include adequate protein, appropriate resistance exercise and body-composition support when possible.
Read our guides to Semaglutide and Tirzepatide, or review our broader GLP-1 Weight Loss Los Angeles pillar page.
Independent background on prescription weight-management medications is available from the NIDDK.
Schedule a comprehensive medical weight-loss evaluation to discuss which approach may be appropriate for you.
